Notice to Annual General Meeting in Modus Therapeutics Holding AB

STOCKHOLM, SWEDEN – 20 April 2021.

The shareholders of Modus Therapeutics Holding AB, 556851-9523, are hereby invited to attend the Annual General Meeting on Monday, May 3rd 2021. Due to the ongoing pandemic, the Annual General Meeting, with the support of temporary legal rules, will be conducted through postal vote in advance only (postal vote). No Annual General Meeting with the opportunity to attend in person or by proxy will take place. Information on the resolutions passed by the Annual General Meeting will be published on May 3rd 2021 as soon as the outcome of the postal voting has been finally compiled.

For more details, please follow the following documents:

Notice for AGM
Annual report
Power of attorney form
Postal voting form

For further information, please contact:

John Öhd, CEO, Modus Therapeutics:

Tel: +46 70 766 8097
E-mail: john.ohd@modustx.com

Nathaniel Dahan or David Dible, Citigate Dewe Rogerson

Tel: +44 20 7638 9571
E-mail: modustx@citigatedewerogerson.com

 

FOR THE EDITORS

About Modus Therapeutics AB

Modus Therapeutics is a Swedish biotech company developing sevuparin with a focus on diseases with high unmet medical need. The Company’s near-term focus is to develop sevuparin for patients with sepsis/septic shock, a severe and often fatal condition. Modus is backed by KDev Investments AB, (part of Karolinska Development AB (Nasdaq Stockholm: KDEV) and Rosetta Capital), The Foundation for Baltic and European Studies (Östersjöstiftelsen) and Praktikerinvest AB.

About sevuparin

Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including anti-inflammatory, anti-adhesive and anti-aggregate effects.  Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration.

About severe systemic inflammation

Severe systemic inflammation conditions (also known as systemic inflammatory response syndrome, SIRS) are feared complications of severe medical conditions such as infection, trauma, and major surgery. It is characterized by an uncontrolled systemic inflammatory response that can progress into shock and multi-organ failure. One such manifestation is septic shock, which is a leading cause of death in intensive care units worldwide, with mortality rates typically exceeding 30%.

In systemic inflammation reactions, vascular hyper-permeability caused by the inflammatory response, may cause significant endothelial damage, plasma leakage and excessive edema formation. The pulmonary circulation is particularly vulnerable leading to respiratory distress, and in time more advanced multi-organ damage ensues. Neutrophil granulocytes, releasing an array of potent inflammatory mediators exhibiting permeability–increasing properties, are critically involved in the capillary-alveolar barrier breakdown.

There is currently no pharmaceutical product available that can be specifically used to treat patients with uncontrolled systemic inflammation such as sepsis. The current standard of care for hospitalized patients relies on aggressive fluid therapy, vasopressors, oxygen, corticoid steroids and mechanical ventilation.